These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30929977)

  • 21. Variability in Trough Total and Unbound Teicoplanin Concentrations and Achievement of Therapeutic Drug Monitoring Targets in Adult Patients with Hematological Malignancy.
    Byrne CJ; Roberts JA; McWhinney B; Fennell JP; O'Byrne P; Deasy E; Egan S; Desmond R; Enright H; Ryder SA; D'Arcy DM; McHugh J
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic/pharmacodynamic targets in adult patients with haematological malignancy.
    Byrne CJ; Roberts JA; McWhinney B; Ryder SA; Fennell JP; O'Byrne P; Deasy E; Egan S; Desmond R; Enright H; D'Arcy DM; McHugh J
    Clin Microbiol Infect; 2017 Sep; 23(9):674.e7-674.e13. PubMed ID: 28267636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors for decreased teicoplanin trough concentrations during initial dosing in critically ill patients.
    Yoshida T; Yoshida S; Okada H; Suzuki A; Niwa T; Suzuki K; Ohmori T; Kobayashi R; Baba H; Suzuki K; Murakami N; Itoh Y; Ogura S
    Pharmazie; 2019 Feb; 74(2):120-124. PubMed ID: 30782263
    [No Abstract]   [Full Text] [Related]  

  • 24. Higher Teicoplanin Blood Level Needed in Elderly Critically Ill Patients.
    Wang L; Chen M; Ye H; Lin X; Li Y; Ruan J; Lin F; Lin Y
    Curr Drug Metab; 2021; 22(14):1124-1131. PubMed ID: 34809542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Necessity of personalized initial loading dose calculation of teicoplanin by clinical pharmacist-examination of the utility of using systemic inflammatory response syndrome score-].
    Nakano T; Nakamura Y; Togawa A; Takata T; Ishikura H; Mishima K; Futagami K
    Yakugaku Zasshi; 2014; 134(12):1367-73. PubMed ID: 25452245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of the pharmacokinetics of Aspen Ceftriaxone and Rocephin in community-acquired meningitis.
    Richards GA; Elliott E; Shaddock EJ; Mushi D; Mzileni M; Ray R; Rulisa S; Seolwane F; Stacey SL; Stoltz A; Venturas JP; Schoeman H
    S Afr Med J; 2013 Sep; 103(12):906-9. PubMed ID: 24300626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose.
    Pea F; Brollo L; Viale P; Pavan F; Furlanut M
    J Antimicrob Chemother; 2003 Apr; 51(4):971-5. PubMed ID: 12654757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors.
    Barbot A; Venisse N; Rayeh F; Bouquet S; Debaene B; Mimoz O
    Intensive Care Med; 2003 Sep; 29(9):1528-34. PubMed ID: 12856119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme.
    Lamont E; Seaton RA; Macpherson M; Semple L; Bell E; Thomson AH
    J Antimicrob Chemother; 2009 Jul; 64(1):181-7. PubMed ID: 19411678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia.
    Mimoz O; Rolland D; Adoun M; Marchand S; Breilh D; Brumpt I; Debaene B; Couet W
    Intensive Care Med; 2006 May; 32(5):775-9. PubMed ID: 16550370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of individual adjustment of initial loading dosage of teicoplanin based on population pharmacokinetics.
    Niwa T; Imanishi Y; Ohmori T; Matsuura K; Murakami N; Itoh Y
    Int J Antimicrob Agents; 2010 May; 35(5):507-10. PubMed ID: 20185275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative pharmacokinetics of teicoplanin and vancomycin.
    Harding I; Sorgel F
    J Chemother; 2000 Nov; 12 Suppl 5():15-20. PubMed ID: 11131959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose regimen to achieve novel target trough concentration in teicoplanin.
    Ueda T; Takesue Y; Nakajima K; Ichki K; Wada Y; Komatsu M; Tsuchida T; Takahashi Y; Ishihara M; Kimura T; Uchino M; Ikeuchi H
    J Infect Chemother; 2014 Jan; 20(1):43-7. PubMed ID: 24462424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simplified dosing regimens of teicoplanin for patient groups stratified by renal function and weight using Monte Carlo simulation.
    Yamada T; Nonaka T; Yano T; Kubota T; Egashira N; Kawashiri T; Oishi R
    Int J Antimicrob Agents; 2012 Oct; 40(4):344-8. PubMed ID: 22818770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analyses of teicoplanin concentrations from 1994 to 2006 from a UK assay service.
    Tobin CM; Lovering AM; Sweeney E; MacGowan AP
    J Antimicrob Chemother; 2010 Oct; 65(10):2155-7. PubMed ID: 20682566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic Drug Monitoring of Teicoplanin in Haematological Malignancy Patients with Febrile Neutropenia and Optimizing Dosage Regimens.
    Hu S; Wang T; You H; Wei S; Song H; Zhang T; Zhang D; Dong Y
    Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):594-601. PubMed ID: 29702731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High risk of cross-reactivity between vancomycin and sequential teicoplanin therapy.
    Hsiao SH; Chou CH; Lin WL; Lee EJ; Liao LH; Chang HJ; Yeh PY; Lin CY; Wu TJ
    J Clin Pharm Ther; 2012 Jun; 37(3):296-300. PubMed ID: 22017186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measurement of Teicoplanin Concentration With Liquid Chromatography-Tandem Mass Spectrometry Method Demonstrates the Usefulness of Therapeutic Drug Monitoring in Hematologic Patient Populations.
    Chae H; Lee JJ; Cha K; Her SH; Kim HY; Han E; Kim M; Kim Y; Cho SY; Lee DG
    Ther Drug Monit; 2018 Jun; 40(3):330-336. PubMed ID: 29746433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Teicoplanin pharmacokinetics in pediatric patients.
    Dufort G; Ventura C; Olivé T; Ortega JJ
    Pediatr Infect Dis J; 1996 Jun; 15(6):494-8. PubMed ID: 8783345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacokinetic and clinical studies on teicoplanin for sepsis by methicillin-cephem resistant Staphylococcus aureus in the pediatric and neonate field].
    Sunakawa K; Nonoyama M; Fujii R; Iwai N; Sakata H; Shirai M; Sato T; Kajino M; Toyonaga Y; Sano T; Naito A; Minagawa K; Niida Y; Oda T; Yokozawa M; Asanuma H; Shimura K; Fujimura M; Kitajima H; Fujinami K; Numazaki K; Fujikawa T; Kobayashi Y; Sato Y; Nishimura T; Iwata S; Tsuchihashi N; Oishi T; Matsumoto S; Motohiro T; Osawa M; Sunahara M; Shirakawa S; Nishida H; Takahashi N; Nakano R; Sai N; Iyoda K; Yoshimitsu K; Ogawa K; Okazaki T; Tsukimoto I; Motoyama O; Takada Y; Kawasaki M; Sunaoshi W; Nakamura S; Ueda Y; Kamata M; Kato T; Chiba M; Ouchi K; Sato S; Horiuchi T; Suzuki K; Shimoyama T; Masaki H; Aikyo M; Kawada M; Banba M; Furukawa S; Okada T; Yamaguchi S; Hirota O; Koizumi S; Wada H; Ohta K; Uehara T; Yukitake K; Mori T; Takakuwa S; Matsuyama K
    Jpn J Antibiot; 2002 Oct; 55(5):656-77. PubMed ID: 12532639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.